The cost-effectiveness of routine childhood varicella vaccination in Germany

Vaccination News Home Page                                            subscribe Vaccination NewsLetter

http://www.elsevier.nl/gej-ng/10/42/35/80/51/57/abstract.html

Please note! As of 2002 online access to full-text articles is available to all readers whose library
  1. subscribes to Vaccine via ScienceDirect or
  2. has a print subscription to Vaccine and has registered for the corresponding ScienceDirect Web Editions.


Vaccine, Vol. 21 (11-12) (2003) pp. 1256-1267
© 2002 Elsevier Science Ltd. All rights reserved.
PII: S0264-410X(02)00431-0
 

The cost-effectiveness of routine childhood varicella vaccination in Germany ¤

K. Banz a * kurt.banz@outcomes.ch , S. Wagenpfeil b, A. Neiss b, A. Goertz c, U. Staginnus c 1 , J. Vollmar c and P. Wutzler d

a Outcomes International, Malzgasse 9, CH-4052 Basel, Switzerland
b Institute for Medical Statistics and Epidemiology, Technical University of Munich, Munich, Germany
c GlaxoSmithKline, Munich, Germany
d Institute for Antiviral Chemotherapy, University of Jena, Jena, Germany

Received 23 October 2001; received in revised form 1 August 2002; accepted 19 August 2002

Abstract

This study explores the economic value of a routine varicella vaccination program for Germany. An age-structured decision analytic model was used to assess the benefits, costs and cost-effectiveness of an immunization program for a period of 30 years. Three interventions were compared with no vaccination: universal vaccination of around 15 months old healthy children, vaccination of susceptible adolescents (11-12 years of age), and the combined strategy. The analysis was conducted from both the societal perspective and the payers', i.e. sickness funds, perspective. Input data were mainly derived from a retrospective survey (analyzed were1334 patient records) and from a seroprevalence study (n=4602 sera). Using a coverage rate of 85% and a vaccine efficacy rate of 86% routine children vaccination could prevent around 611,000 varicella cases and over 4700 major complications per year. Average yearly cost savings for the society are 51.3 million Euro. The benefit-cost ratio (BCR) is 4.12. From the third-party payer's perspective, the BCR is 1.75 which is a consequence of significant reimbursement of parent's lost earnings by German sickness funds. The adolescent vaccination strategy has a favorable BCR ratio of 8.44 from the societal perspective, but clearly inferior medical effects. The combined vaccination strategy showed similar results as the children strategy. Routine childhood varicella vaccination appears to be a highly efficient strategy to reduce the burden of varicella and results in significant savings for both the society and the payers.

Keywords: Varicella; Vaccination; Cost-effectiveness

*Corresponding author. Tel.: +41-61-227-72-55; fax: +41-61-227-72-27.

1Former with GlaxoSmithKline Biologicals, Rixensart, Belgium.

 

¤This study was supported by a grant from GlaxoSmithKline.

Full text supplied by [ScienceDirect]

© Copyright 2003, Elsevier Science, All rights reserved.

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.